HDAC9 and Thrombocytopenia: It has been proven critical for mass production of platelets in vitro (36), and HDAC inhibitors (HDACi), widely used to treat malignancies, have been associated with thrombocytopenia, likely due to decreased megakaryopoiesis and thrombopoiesis (37).